Robert J. Spiegel
Known title: DirectorCIK: 0001492256
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
RenovoRx publishes peer-reviewed case series in oncology journal. RenovoRx reported that researchers at Hackensack Meridian Health’s Jersey Shore University Medical Center published a peer-reviewed case series in Case Reports in Oncology. This update highlights clinical activity involving the company's products, adding to the scientific evidence base. The stock currently trades near its 52-week low, with an average analyst target significantly higher than the current price.
Transaction History
| GERN | ▲ Buy | Grant | 6,351 | $8K | 9/30/2026 | View on chart |
| GERN | ▲ Buy | Grant | 6,103 | $8K | 6/30/2026 | View on chart |
| GERN | ▲ Buy | Grant | 5,243 | $8K | 3/31/2026 | View on chart |
| GERN | ▲ Buy | Grant | 5,918 | $8K | 12/31/2025 | View on chart |
| GERN | ▲ Buy | Grant | 5,702 | $8K | 9/30/2025 | View on chart |
| GERN | ▲ Buy | Grant | 5,540 | $8K | 6/30/2025 | View on chart |
| GERN | ▲ Buy | Grant | 4,913 | $8K | 3/31/2025 | View on chart |
| GERN | ▲ Buy | Grant | 2,206 | $0 | 12/31/2024 | View on chart |
| GERN | ▲ Buy | Grant | 1,767 | $0 | 9/30/2024 | View on chart |
| GERN | ▲ Buy | Grant | 1,916 | $0 | 6/28/2024 | View on chart |
| GERN | ▲ Buy | Grant | 2,462 | $0 | 3/29/2024 | View on chart |
| RNXT | ▲ Buy | Open Market | 40,983 | — | 1/26/2024 | View on chart |
| GERN | ▲ Buy | Grant | 3,406 | $0 | 12/29/2023 | View on chart |
| GERN | ▲ Buy | Grant | 3,390 | $0 | 9/29/2023 | View on chart |
| BGMS | ▲ Buy | Grant | 21,219 | $0 | 6/30/2023 | View on chart |
| GERN | ▲ Buy | Grant | 2,239 | $0 | 6/30/2023 | View on chart |
| GERN | ▲ Buy | Grant | 3,312 | $0 | 3/31/2023 | View on chart |
| GERN | ▲ Buy | Grant | 2,970 | $0 | 12/30/2022 | View on chart |
| GERN | ▲ Buy | Grant | 3,071 | $0 | 9/30/2022 | View on chart |
| GERN | ▲ Buy | Grant | 4,637 | $0 | 6/30/2022 | View on chart |
| BGMS | ▲ Buy | Grant | 15,822 | $0 | 6/14/2022 | View on chart |
| GERN | ▲ Buy | Grant | 5,284 | $0 | 3/31/2022 | View on chart |
| GERN | ▲ Buy | Grant | 5,891 | $0 | 12/31/2021 | View on chart |
| GERN | ▲ Buy | Grant | 5,246 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses
Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.